Obermatt
See Similar Stocks →

Flags

Financial distress

Teva Pharmaceutical Industries

TLV:TEVA · IL0006290147
PharmaceuticalsLarge

360

23
EV / EBIT56
Price / Owner Earnings53
Owner Earnings Yield42
Dividend Yield1
Price/Sales61
EV / Gross Profit37
Price/Book34
Return on Capital61
Cash Return on Capital39
Return on Equity79
EBIT Margin54
Gross Profitability14
Cash Conversion28
Accruals69
Owner Earnings Margin33
Sales growth18
Profit Growth92
Long-Term EPS Growth20
Owner Earnings Growth100
Reinvestment46
Price momentum90
Debt load7
Refinancing16
Debt Payback7
Liquidity39
Analyst ratings73
Opinion Changes58
Price Target Upside70
Market mood21
Value Creation16/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Teva Pharmaceutical Industries generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryIsrael
IndustryPharmaceuticals
SizeLarge
TypePublic Company
ExchangeNYSE
Founded1944
Employees21,377
Websitetevapharm.com
ISINIL0006290147
Last UpdateApr 2, 2026
Index & Theme
RespiratoryPain ManagementPsychiatryChronic DiseasesOphthalmologyNeurologyCentral Nervous SystemOncologyBiopharmaHealth CareMedicalPharmaceutical

Description

Teva Pharmaceutical Industries Limited (Teva), a biopharmaceutical company, engages in the development, manufacturing, marketing and distribution of generics, innovative medicines and biopharmaceuticals in the United States and Europe. Business Segm…

Analysis

Middle-of-the-road

Teva Pharmaceutical Industries Limited sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

On valuation, the picture is fair. The owner-earnings multiple stands at 19.9×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 6% a year, against analyst forecasts of 4%. The price, in other words, assumes less than the experts do.

Growth is moderate; the safety picture is fragile. The company scores 16/20 on our value-creation score: strong value creator.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
38
2023202420252026

All-time high

43

Mar 2026

All-time low

10

Jan 2023

Average rank

26

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
61
59
87
97
Price/Earnings
36
91
97
97
Price/Book
34
45
71
92
Dividend Yield
1
1
1
1
Value (overall)
31
60
77
78

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Teva Pharmaceutical Industries with its peers
Laboratorios Farmaceuticos Rovi
MCE:ROVI
46
CountrySpain
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Faes Farma
MCE:FAE
44
CountrySpain
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Recordati
MIL:REC
54
CountryItaly
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Perrigo
NYQ:PRGO
8
CountryIreland
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Cohance Lifesciences
NSI:COHANCE
37
CountryCyprus
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Mediwound
NMQ:MDWD
25
CountryIsrael
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →